


COMPANY UPDATE


Singapore Exchange (SGX SP)

Stellar Month For All Business Segments

For Sep 24, SGX reported strong operating statistics which saw SDAV reaching a two-year high, driven by increased market turnover value for China-linked SGX-listed companies. Total derivative traded volumes also surged to a four-year high, driven by the equity derivatives and commodities segments. However, with a lack of near-term catalysts, we still opine that SGX is fairly valued at current price levels. Maintain HOLD but with a higher PE-based target price of S\$11.83 (S\$11.62 previously).

SECURITIES DAILY AVERAGE VALUE (SDAV) DERIVATIVES DAILY AVERAGE VALUE (DDAV)

Source: Singapore Exchange, UOB Kay Hian



Source: Singapore Exchange, UOB Kay Hian

WHAT'S NEW

Robust month for cash equities. Slightly above expectations, Singapore Exchange (SGX) reported its Sep 24 monthly statistics which showed that securities daily average value (SDAV) surged sharply (+66.9% yoy, +5.6% mom) to S\$1.44b, the highest since May 22. Driven by China's announced stimulus measures, this led to an increase in total value traded for China-linked SGX listed companies along with the financial and telco sectors. We maintain our expectations that SDAV would stay elevated in the following months as uncertainty over the global economy, upcoming US elections in Nov 24 and the US fed interest rate policy would likely increase trading velocity moving forward.

Derivatives volume at four-year high. Slightly above expectations, derivatives daily average volume (DDAV) surged (+35.2% yoy, +28.0% mom) in Sep 24, driven by record-high volumes across most asset classes. Total equity index futures volumes rose 37.0% yoy to hit a two-year high, largely driven by the FTSE China A50 Index Futures which saw volumes skyrocket (+59.8% yoy, +59.7% mom) on the back of China's announced stimulus measures. Other major equity indexes such as the FTSE Taiwan index futures (+11.3% yoy, -11.0% mom), MSCI Singapore index futures (+12.9% yoy, -9.6% mom) and NSE IFSC Nifty 50 Index Futures (+14.6% yoy, -2.9% mom) also grew yoy. Moving forward, we still expect positive total traded equity derivatives volumes growth in FY25 from an uncertain macroeconomic outlook boosting demand for risk management.

KEY FINANCIALS

Year to 30 Jun (\$m)	2023	2024	2025F	2026F	2027F
Net turnover	1,194	1,232	1,344	1,396	1,443
EBITDA	688	702	781	803	823
Operating profit	590	606	679	703	723
Net profit (rep./act.)	571	598	575	595	612
Net profit (adj.)	503	526	575	595	612
EPS (S\$ cent)	45.5	48.0	52.5	54.3	55.9
PE (x)	25.7	24.4	22.3	21.6	21.0
P/B (x)	7.4	6.4	5.8	5.4	5.0
EV/EBITDA (x)	17.9	17.5	15.8	15.3	15.0
Dividend yield (%)	2.8	2.9	3.1	3.3	3.5
Net margin (%)	47.8	48.5	42.8	42.7	42.4
Net debt/(cash) to equity (%)	(5.0)	(7.8)	(10.3)	(10.4)	(10.8)
Interest cover (x)	n.a.	n.a.	n.a.	n.a.	n.a.
ROE (%)	35.2	32.7	28.0	26.6	25.3
UOBKH/Consensus (x)	-	-	0.99	1.00	0.97

Source: Singapore Exchange, Bloomberg, UOB Kay Hian

HOLD

(Maintained)

Share Price	S\$11.71
Target Price	S\$11.83
Upside	+1.0%
(Previous TP	S\$11.62)

COMPANY DESCRIPTION

Singapore Exchange owns and operates Singapore's Securities and derivatives exchange and their related clearing houses. The company also provides ancillary securities processing and information technology services to participants in the financial sector.

STOCK DATA

GICS sector	Financials
Bloomberg ticker:	SGX SP
Shares issued (m):	1,070.8
Market cap (S\$m):	12,539.1
Market cap (US\$m):	9,581.4
3-mth avg daily t'over (US\$m):	22.6

Price Performance (%)

52-week high/low S\$11.85/S\$8.87

1mth	3mth	6mth	1yr	YTD
4.3	20.1	28.3	19.9	19.1

Major Shareholders %

None	-
FY25 NAV/Share (\$S)	2.00
FY25 Net Cash/Share (\$S)	0.21

PRICE CHART



Source: Bloomberg

ANALYST(S)

Lleleythan Tan Yi Rong

+65 6590 6624

yirong@uobkayhian.com

Heidi Mo

+65 6590 6630

heidimo@uobkayhian.com

- FICC: Stellar performance.** In line with expectations, the fixed income, currencies and commodities (FICC) segment continued to outperform with total forex volumes (+34.8% yoy, -0.7% mom) surging higher yoy in Sep 24, just shy of the previous record set in Aug 24. The strong performance was driven by the three main currency pairs. Total trading volumes for USD/CNH futures (+22.9% yoy, +1.5% mom), KRW/USD futures (+114.3% yoy, -18.6% mom) and INR/USD futures (+54.9% yoy, -1.9% mom) grew yoy. Following China's stimulus announcements, the commodities segment (+29.1% yoy, +14.6% mom) saw volumes surging to record highs, largely led by iron ore futures (+29.0% yoy, +13.5% mom) and SGX SICOM rubber futures (+60.0% yoy, +60.4% mom).

STOCK IMPACT

- MAS review group update.** As a recap, the Monetary Authority of Singapore (MAS) announced that a review group has been set up to review and strengthen the equities market in Singapore. The group will recommend a set of measures and complete its report within 12 months. It was recently announced by the group's chair that the review group does not intend to wait till the end of the 12-month review period before implementing proposals and would carry out any potential measures in phases. Also, some measures that have been discussed include: a) providing incentives and encouraging quality domestic and regional companies to list on SGX; b) improving market liquidity and participation by facilitating price discovery, broadening stock indices and expanding the pool of equity market derivatives; and c) re-evaluating regulatory structures and approaches such as streamlining the prospectus disclosure for IPOS while sharpening the focus on material disclosures and disclosure quality.

EARNINGS REVISION/RISK

- We increase our FY25-27 PATMI forecasts by 1-2%,** on the back of higher SDAV and equity derivatives assumptions. For FY25-27, our headline PATMI estimates are S\$575.3m (S\$565.1m previously), S\$595.3m (S\$586.9m previously) and \$612.4m (S\$604.9m previously) respectively.


VALUATION/RECOMMENDATION

- Maintain HOLD with a slightly higher PE-based target price of S\$11.83 (S\$11.62 previously),** pegged to 22x PE multiple, to SGX's historical forward average mean to FY25 earnings.
- In our view, we reckon that there are no near-term catalysts to justify a higher valuation. Despite a lacklustre yield of about 3.1%, we like still SGX for its resilient business model that benefits from the global economic uncertainty but recommend waiting for better entry points.

SHARE PRICE CATALYST


- Longer-than-expected period of trading volatility.
- Higher-than-expected SDAV and DDAV.
- Earnings-accretive acquisitions.

TOTAL ANNUAL SECURITIES TRADED VALUE (\$\$M)




Source: Singapore Exchange, UOB Kay Hian

TOTAL DERIVATIVE CONTRACTS TRADED



Source: Singapore Exchange, UOB Kay Hian

SEGMENTAL HALF YEARLY REVENUE (\$\$M)



Source: Singapore Exchange, UOB Kay Hian

HISTORICAL FORWARD PE



Source: Bloomberg, UOB Kay Hian

PROFIT & LOSS

Year to 30 Jun (\$'m)	2024	2025F	2026F	2027F
Net turnover	1,231.7	1,343.6	1,395.6	1,443.1
EBITDA	702.2	780.6	803.0	823.4
Deprec. & amort.	95.9	101.7	100.2	100.4
EBIT	606.4	678.9	702.7	723.0
Total other non-operating income	117.1	17.7	17.7	17.7
Associate contributions	(14.5)	(14.5)	(14.5)	(14.5)
Net interest income/(expense)	0.0	0.0	0.0	0.0
Pre-tax profit	709.0	682.2	706.0	726.2
Tax	(111.4)	(107.2)	(111.0)	(114.1)
Minorities	0.3	0.3	0.3	0.3
Net profit	597.9	575.3	595.3	612.4
Net profit (adj.)	525.9	575.3	595.3	612.4

BALANCE SHEET

Year to 30 Jun (\$'m)	2024	2025F	2026F	2027F
Fixed assets	189.6	163.0	137.7	112.4
Other LT assets	1,548.3	1,533.9	1,519.4	1,504.9
Cash/ST investment	795.7	864.8	884.2	914.1
Other current assets	1,451.3	1,552.4	1,599.4	1,642.4
Total assets	3,985.0	4,114.1	4,140.8	4,173.8
ST debt	0.0	0.0	0.0	0.0
Other current liabilities	1,238.5	1,183.0	1,026.5	880.6
LT debt	643.1	643.1	643.1	643.1
Other LT liabilities	142.2	142.2	142.2	142.2
Shareholders' equity	1,959.8	2,144.4	2,327.6	2,506.5
Minority interest	1.3	1.4	1.4	1.4
Total liabilities & equity	3,985.0	4,114.1	4,140.8	4,173.8

CASH FLOW

Year to 30 Jun (\$'m)	2024	2025F	2026F	2027F
Operating	615.8	534.4	506.2	538.0
Pre-tax profit	723.5	696.6	720.4	740.7
Tax	(112.3)	(107.2)	(111.0)	(114.1)
Deprec. & amort.	95.9	101.7	100.2	100.4
Associates	0.0	0.0	0.0	0.0
Working capital changes	0.7	(156.6)	(203.5)	(188.9)
Investing	(137.9)	(75.0)	(75.0)	(75.0)
Capex (growth)	(4.7)	0.0	0.0	0.0
Investment	(207.4)	0.0	0.0	0.0
Proceeds from sale of assets	108.1	0.0	0.0	0.0
Others	(33.8)	(75.0)	(75.0)	(75.0)
Financing	(459.7)	(390.4)	(411.8)	(433.2)
Dividend payments	(364.9)	(390.4)	(411.8)	(433.2)
Proceeds from borrowings	0.0	0.0	0.0	0.0
Loan repayment	(375.4)	0.0	0.0	0.0
Others/interest paid	280.7	0.0	0.0	0.0
Net cash inflow (outflow)	18.2	69.1	19.4	29.8
Beginning cash & cash equivalent	777.3	795.7	864.8	884.2
Changes due to forex impact	0.2	0.0	0.0	0.0
Ending cash & cash equivalent	795.7	864.8	884.2	914.1

KEY METRICS

Year to 30 Jun (%)	2024	2025F	2026F	2027F
Profitability				
EBITDA margin	57.0	58.1	57.5	57.1
Pre-tax margin	57.6	50.8	50.6	50.3
Net margin	48.5	42.8	42.7	42.4
ROA	15.4	14.2	14.4	14.7
ROE	32.7	28.0	26.6	25.3
Growth				
Turnover	3.1	9.1	3.9	3.4
EBITDA	2.1	11.2	2.9	2.5
Pre-tax profit	5.2	(3.8)	3.5	2.9
Net profit	4.7	(3.8)	3.5	2.9
Net profit (adj.)	4.5	9.4	3.5	2.9
EPS	5.4	9.4	3.5	2.9
Leverage				
Debt to total capital	24.7	23.1	21.6	20.4
Debt to equity	32.8	30.0	27.6	25.7
Net debt/(cash) to equity	(7.8)	(10.3)	(10.4)	(10.8)

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries or jurisdictions by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2024, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W